Search - tctmd.com

Displaying 301 - 320 of 480

Sort: Relevancy | Date

Presentation TVT 2016

Incidence and Clinical Impact of Atrial Fibrillation in TAVR Patients

Presenter: Philippe Généreux

June 16, 2016

Presentation EuroPCR 2016

LAA Occlusion vs Standard Care In Patients With Atrial Fibrillation And Intracerebral Hemorrhage

Presenter: Jens Erik Nielsen-Kudsk

May 20, 2016

Presentation

A-fib Associated With Increased Mortality in Patients Undergoing TAVR: PARTNER Analysis

Presenter: Angelo Biviano

January 07, 2016

Presentation

Transradial vs Transfemoral Access in Rescue PCI After Fibrinolytic Therapy

Presenter: MB. Kadakia

December 20, 2015

Presentation

Time to Cost-Effectiveness After Stroke Reduction Strategies in A-fib: Warfarin vs Novel Oral Anticoagulants (NOACs) vs Left Atrial Appendage (LAA) Closure

Presenter: Vivek Y. Reddy

December 13, 2015

Presentation TCT 2015

Incidence, Significance, and Management of New-Onset Atrial Fibrillation After TAVR

Presenter: Isaac George, Augusto D. Pichard, Alec S. Vahanian

October 15, 2015

Presentation TCT 2015

Miscellaneous Emerging Technologies 4: Stent-Based Pulmonary Vein Isolation Approach to Atrial Fibrillation

Presenter: Greg L. Kaluza, Joachim Schofer, Glenn Van Langenhove

October 15, 2015

Presentation TCT 2015

Putting It All Together: How to Manage the Patient With Atrial Fibrillation Undergoing PCI

Presenter: Gerhard C. Schuler, Matthew J. Price

October 14, 2015

Presentation TCT 2015

Considerations Regarding Renal Function in the Patient With Atrial Fibrillation

Presenter: Gerhard C. Schuler, C. Michael Gibson

October 14, 2015

Presentation TCT 2015

Device-Detected, Subclinical Atrial Fibrillation: Now What?

Presenter: Gerhard C. Schuler, Freek W.A. Verheugt

October 14, 2015

Presentation TCT 2015

Alternatives to Anticoagulation: Left Atrial Appendage Occlusion Devices

Presenter: Gerhard C. Schuler, Matthew J. Price

October 14, 2015

Presentation TCT 2015

The PIONEER Trial (Rivaroxaban in Patients With ACS and Atrial Fibrillation): Design, Rationale, and Status

Presenter: Pascal Vranckx, Roxana Mehran

October 14, 2015

Presentation TCT 2015

The RE-DUAL PCI Trial (Dabigatran in Patients With ACS and Atrial Fibrillation): Design, Rationale, and Status

Presenter: Pascal Vranckx, Deepak L. Bhatt

October 14, 2015

Presentation TCT 2015

A Trial of Apixaban in Patients With Atrial Fibrillation and ACS/PCI: Design, Rationale, and Status

Presenter: Pascal Vranckx, Renato D. Lopes

October 14, 2015

Presentation TCT 2015

Can We Drop Aspirin? Pharmacodynamic Insights on Adding an Oral Anticoagulant to Antiplatelet Therapy With and Without Aspirin

Presenter: Pascal Vranckx, Freek W.A. Verheugt

October 14, 2015

Presentation TCT 2015

Reversal Agents for Factor Xa Inhibitors

Presenter: Lisa K. Jennings, Matthew T. Roe

October 14, 2015

Presentation TCT 2015

Rivaroxaban: Analysis of Efficacy, Safety, and Special Considerations

Presenter: Lisa K. Jennings, Matthew T. Roe, Manesh R. Patel

October 14, 2015

Presentation TCT 2015

Apixaban: Analysis of Efficacy, Safety, and Special Considerations

Presenter: Lisa K. Jennings, Matthew T. Roe

October 14, 2015

Presentation TCT 2015

Dabigatran: Analysis of Efficacy, Safety, and Special Considerations (Including Reversal Agents)

Presenter: Lisa K. Jennings, Matthew T. Roe, Pascal Vranckx

October 14, 2015

Presentation TCT 2015

TCT 57: A Cost Analysis of Bleed Complications From 2 Stroke Prevention Strategies in Nonvalvular Atrial Fibrillation: Left Atrial Appendage Closure Versus Warfarin

Presenter: Jacqueline Saw, Steven J. Yakubov, Matthew J. Price

October 13, 2015

Advertisement

Incidence and Clinical Impact of Atrial Fibrillation in TAVR Patients

LAA Occlusion vs Standard Care In Patients With Atrial Fibrillation And Intracerebral Hemorrhage

A-fib Associated With Increased Mortality in Patients Undergoing TAVR: PARTNER Analysis

Transradial vs Transfemoral Access in Rescue PCI After Fibrinolytic Therapy

Time to Cost-Effectiveness After Stroke Reduction Strategies in A-fib: Warfarin vs Novel Oral Anticoagulants (NOACs) vs Left Atrial Appendage (LAA) Closure

Incidence, Significance, and Management of New-Onset Atrial Fibrillation After TAVR

Miscellaneous Emerging Technologies 4: Stent-Based Pulmonary Vein Isolation Approach to Atrial Fibrillation

Putting It All Together: How to Manage the Patient With Atrial Fibrillation Undergoing PCI

Considerations Regarding Renal Function in the Patient With Atrial Fibrillation

Device-Detected, Subclinical Atrial Fibrillation: Now What?

Alternatives to Anticoagulation: Left Atrial Appendage Occlusion Devices

The PIONEER Trial (Rivaroxaban in Patients With ACS and Atrial Fibrillation): Design, Rationale, and Status

The RE-DUAL PCI Trial (Dabigatran in Patients With ACS and Atrial Fibrillation): Design, Rationale, and Status

A Trial of Apixaban in Patients With Atrial Fibrillation and ACS/PCI: Design, Rationale, and Status

Can We Drop Aspirin? Pharmacodynamic Insights on Adding an Oral Anticoagulant to Antiplatelet Therapy With and Without Aspirin

Reversal Agents for Factor Xa Inhibitors

Rivaroxaban: Analysis of Efficacy, Safety, and Special Considerations

Apixaban: Analysis of Efficacy, Safety, and Special Considerations

Dabigatran: Analysis of Efficacy, Safety, and Special Considerations (Including Reversal Agents)

TCT 57: A Cost Analysis of Bleed Complications From 2 Stroke Prevention Strategies in Nonvalvular Atrial Fibrillation: Left Atrial Appendage Closure Versus Warfarin

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content